Navigation Links
Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
Date:3/4/2010

WASHINGTON, March 4 /PRNewswire/ -- Daiichi Sankyo has joined the National Cherry Blossom Festival as co-chair of the Centennial Celebration Host Committee, spearheading the efforts over the next several years to commemorate, in 2012, the 100-year anniversary of the gift of cherry blossom trees from Tokyo to Washington, D.C.

Daiichi Sankyo, a global leader in pharmaceutical innovation since 1899, has a unique connection to the exotic cherry blossoms that famously line the tidal basin in D.C. Nearly a century ago, a world-famous chemist and Daiichi Sankyo's first president, Dr. Jokichi Takamine, had a vision to create a bridge of friendship between the two cities.  As a long-time resident in the U.S., he realized this vision by orchestrating a gift of 3,000 cherry trees on behalf of Tokyo as a symbol of friendship between the two nations.  Today, the National Cherry Blossom Festival and cherry trees draw U.S. and international visitors to Washington each year and remain a symbol of international friendship.

As co-chair of the Host Committee for the National Cherry Blossom Festival, Daiichi Sankyo will work with Festival organizers for the next several years to shape the Centennial Celebration by providing ideas, resources and funding to plan for a spectacular 100-year celebration.  

"The gifting of the cherry trees was an international sign of friendship and serves as inspiration for our global philanthropic mission, which is dedicated to listening, learning and making contributions that have a real impact on people's lives," said Takashi Shoda, chief executive officer of Daiichi Sankyo Co., Ltd. "Through continued drug development and discovery of therapies that improve the quality of life for patients around the world, our company will continue building on the traditions and scientific legacy of our forefathers and their vision for international collaboration and friendship."

The annual blooming of cherry blossoms symbolizes the balance of East and West, beauty and strength, and eternal renewal amidst seasonal change – a perennial reminder of the gift of friendship between Japan and the United States.

"We are thrilled that Daiichi Sankyo is joining us to create a momentous, once-in-a-lifetime celebration for Washington, D.C. and the nation," said Diana Mayhew, president of the National Cherry Blossom Festival. "The Centennial Celebration will embrace the history and traditions that the Festival honors, while setting the stage for the next 100 years. With Daiichi Sankyo's commitment and active participation, 2012 will surely be an unforgettable year."

About the National Cherry Blossom Festival

The National Cherry Blossom Festival is Washington, D.C.'s and the nation's greatest springtime celebration.  The 2010 Festival, March 27April 11, includes three spectacular weekends and daily events featuring diverse and creative programming promoting traditional and contemporary arts and culture, natural beauty, and community spirit.  The 2010 Festival commemorates the 98th anniversary of the gift of the cherry blossom trees and the enduring friendship between United States and Japan.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Company, Ltd. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

For schedules and information visit www.nationalcherryblossomfestival.org or call the Festival hotline at (877) 44BLOOM.

SOURCE Daiichi Sankyo

Back to top

RELATED LINKS
http://www.daiichisankyo.com

'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
4. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
5. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
6. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
7. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
8. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
9. Bumrungrad - The Mayo Clinic of Asia - Joins MediBid.com as a Bidding Facility
10. Yvonne Verburgt Joins the Avrio Executive Team as Vice President of Business Development and Marketing
11. Lumetra PSO Joins Forces With iSOFT Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... NORRITON, Pa. , Feb. 8, 2016 /PRNewswire/ ... of November Research Group (NRG),s pharmacovigilance technology ... pharmacovigilance system-related consulting services and an Oracle Argus ... compliance services to Life Sciences companies. ... strengthens and expands HighPoint,s life sciences capabilities and ...
(Date:2/8/2016)... Switzerland and PALO ALTO, Calif. , Feb. ... and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical ... of retinal disease, announced today agreements for the clinical ... will manufacture material at multiple sites, including Slough (UK), ... --> --> Retinal diseases, such as ...
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Association of Home ... and the Home Health and Hospice ICD-10 Transition Workgroup are working closely with ... guidance and clarifications, to address concerns over the use of 'A' as the ...
Breaking Medicine News(10 mins):